Literature DB >> 25164154

Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation.

M Camilleri1, D A Drossman, G Becker, L R Webster, A N Davies, G M Mawe.   

Abstract

BACKGROUND: Opioids are effective for acute and chronic pain conditions, but their use is associated with often difficult-to-manage constipation and other gastrointestinal (GI) effects due to effects on peripheral μ-opioid receptors in the gut. The mechanism of opioid-induced constipation (OIC) differs from that of functional constipation (FC), and OIC may not respond as well to most first-line treatments for FC. The impact of OIC on quality of life (QoL) induces some patients to decrease or stop their opioid therapy to relieve or avoid constipation.
PURPOSE: At a roundtable meeting on OIC, a working group developed a consensus definition for OIC diagnosis across disciplines and reviewed current OIC treatments and the potential of treatments in development. By consensus, OIC is defined as follows: 'A change when initiating opioid therapy from baseline bowel habits that is characterized by any of the following: reduced bowel movement frequency, development or worsening of straining to pass bowel movements, a sense of incomplete rectal evacuation, or harder stool consistency'. The working group noted the prior validation of a patient response outcome and end point for clinical trials and recommended future efforts to create treatment guidelines and QoL measures specific for OIC. Details from the working group's discussion and consensus recommendations for patient care and research are presented in this article.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  opioid-induced constipation; pain; palliative care; quality of life; μ-opioid receptor

Mesh:

Substances:

Year:  2014        PMID: 25164154      PMCID: PMC4358801          DOI: 10.1111/nmo.12417

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  55 in total

Review 1.  Incidence, prevalence, and management of opioid bowel dysfunction.

Authors:  M Pappagallo
Journal:  Am J Surg       Date:  2001-11       Impact factor: 2.565

2.  Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation.

Authors:  Sara Nullens; Tyler Nelsen; Michael Camilleri; Duane Burton; Deborah Eckert; Johanna Iturrino; Maria Vazquez-Roque; Alan R Zinsmeister
Journal:  Gut       Date:  2011-12-16       Impact factor: 23.059

Review 3.  Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review.

Authors:  Jan Gaertner; Waldemar Siemens; Michael Camilleri; Andrew Davies; Douglas A Drossman; Lynn R Webster; Gerhild Becker
Journal:  J Clin Gastroenterol       Date:  2015-01       Impact factor: 3.062

4.  Low-dose oral naloxone reverses opioid-induced constipation and analgesia.

Authors:  Maywin Liu; Eric Wittbrodt
Journal:  J Pain Symptom Manage       Date:  2002-01       Impact factor: 3.612

5.  Treatment guidelines for hepatic encephalopathy.

Authors:  J Richard Thompson
Journal:  Pharmacotherapy       Date:  2010-05       Impact factor: 4.705

6.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

7.  Morphine tolerance in the mouse ileum and colon.

Authors:  Gracious R Ross; Bichoy H Gabra; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2008-08-05       Impact factor: 4.030

8.  Gastrointestinal side effects in chronic opioid users: results from a population-based survey.

Authors:  S F Cook; L Lanza; X Zhou; C T Sweeney; D Goss; K Hollis; A W Mangel; S E Fehnel
Journal:  Aliment Pharmacol Ther       Date:  2008-03-21       Impact factor: 8.171

Review 9.  Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.

Authors:  Davide Tassinari; Sergio Sartori; Emiliano Tamburini; Emanuela Scarpi; William Raffaeli; Paola Tombesi; Marco Maltoni
Journal:  J Palliat Med       Date:  2008-04       Impact factor: 2.947

Review 10.  Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.

Authors:  S J Panchal; P Müller-Schwefe; J I Wurzelmann
Journal:  Int J Clin Pract       Date:  2007-05-04       Impact factor: 2.503

View more
  77 in total

Review 1.  Evolving paradigms in the treatment of opioid-induced bowel dysfunction.

Authors:  Jakob Lykke Poulsen; Christina Brock; Anne Estrup Olesen; Matias Nilsson; Asbjørn Mohr Drewes
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 2.  Naloxegol: a review of its use in patients with opioid-induced constipation.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

Review 3.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

4.  Randomized phase 3 and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer.

Authors:  N Katakami; T Harada; T Murata; K Shinozaki; M Tsutsumi; T Yokota; M Arai; Y Tada; M Narabayashi; N Boku
Journal:  Ann Oncol       Date:  2018-04-18       Impact factor: 32.976

Review 5.  Opioid-induced constipation: advances and clinical guidance.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Ther Adv Chronic Dis       Date:  2016-01-25       Impact factor: 5.091

Review 6.  The role of naloxegol in the management of opioid-induced bowel dysfunction.

Authors:  Wojciech Leppert; Jaroslaw Woron
Journal:  Therap Adv Gastroenterol       Date:  2016-05-26       Impact factor: 4.409

Review 7.  Opioid misuse in gastroenterology and non-opioid management of abdominal pain.

Authors:  Eva Szigethy; Mitchell Knisely; Douglas Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-15       Impact factor: 46.802

Review 8.  Opioid-Related Constipation in Patients With Non-cancer Pain Syndromes: a Review of Evidence-Based Therapies and Justification for a Change in Nomenclature.

Authors:  Darren M Brenner; Emily Stern; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2017-03

9.  Naldemedine (Symproic) for the Treatment Of Opioid-Induced Constipation.

Authors:  Kenneth Hu; Mary Barna Bridgeman
Journal:  P T       Date:  2018-10

Review 10.  New developments in the treatment of opioid-induced gastrointestinal symptoms.

Authors:  Jasper Pannemans; Tim Vanuytsel; Jan Tack
Journal:  United European Gastroenterol J       Date:  2018-08-27       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.